Physician profile
Christine Weng
NPI 1306572805
$3,406.85
in general payments reported to CMS, 2019-2025
12 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $643 · 2023: $954 · 2024: $803 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,597.91 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Ozurdex |
| Bausch & Lomb Americas INC. | $732.24 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $368.62 | 2022-2025 | Precision 1, Simbrinza, Precision 7 |
| Tarsus Pharmaceuticals, INC. | $139.56 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $122.59 | 2022-2023 | Tyrvaya |
| Horizon Therapeutics Plc | $120.74 | 2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $114.40 | 2023 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $80.16 | 2025 | Izervay |
| Biotissue Holdings INC. | $60.30 | 2024-2025 | |
| Dompe US, INC. | $24.70 | 2025 | Oxervate |
| Genentech USA, INC. | $22.98 | 2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $22.65 | 2025 | Yutiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.